Referencing the market in general by comparing shares outstanding of biotechs through the multiple stages of development through to market.
OK, I can see from here this will be pointless. "You should be more concerned with a CEO that forces his own agenda without fully considering the benefit of such a decision. " What???? Are we talking about the same company here????
Anyone who chooses to believe the company lied when they said they have funds to cover expenses through 2015, including the expanded trials and increased burn rate, go ahead. This was not an opinion it was a statement made within the past month.
Anyone who chooses to believe the company lied about their strategy in only considering a R/S if they could not up-list organically, go ahead. Again not an opinion, company strategy that has been expressed multiple times.
A CEOs statements are most definitely of consequence, that is why they are chosen so carefully.
If at this point you still disagree....I guess my research and understanding has brought me to a different place. I am more than open to a presentation of actual facts to lend credence to the R/S discussion, but simply saying a CEO can change his mind and go against company strategy when there is no reason to change the current strategy is just not a reasonable argument.
And with that,
Good night,
Sleep tight,
ONCS' future,
Is certainly bright :-)
News 
Market Data 
Discover 
